Moreover, for advanced clinical‐stage cancer types, the AUCs were as follows: CEA (0.817), anti‐FIRΔexon2 Abs (0.703), anti‐p53 Abs (0.697) anti‐SOHLH1 Abs (0.648), and CA19‐9 (0.644; Figure 4B). This evidence concerns the gene TP53 and cancer.